de751aae-bc7a-4d70-9d06-4417be4facae
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.500
- HYPOXIA+0.400
- PROTEIN_SECRETION+0.400
- ANDROGEN_RESPONSE+0.300
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- ESTROGEN_RESPONSE_LATE+0.300
- UV_RESPONSE_DN+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- DNA_REPAIR-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- E2F_TARGETS-0.200
- INFLAMMATORY_RESPONSE-0.200
- MYC_TARGETS_V2-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.798 |
| 2 | SRR15069611 | — | — | 0.797 |
| 3 | TCGA-BL-A13J-01A-11R-A10U-07 | — | — | 0.790 |
| 4 | SRR8613758 | — | C | 0.784 |
| 5 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.774 |
| 6 | TCGA-AN-A0XO-01A-11R-A109-07 | — | C | 0.765 |
| 7 | TCGA-AR-A1AU-01A-11R-A12P-07 | — | A | 0.751 |
| 8 | SRR8613703 | — | D | 0.747 |
| 9 | TCGA-AQ-A0Y5-01A-11R-A14M-07 | — | C | 0.741 |
| 10 | TCGA-A1-A0SM-01A-11R-A084-07 | — | C | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |